First-line chemotherapy for metastatic breast cancer in patients ≥75 years: A retrospective single-centre analysis

被引:16
|
作者
Debled, Marc [1 ]
Madranges, Nicolas [1 ]
Mertens, Cecile [1 ]
Durand, Michel [1 ]
Brouste, Veronique [1 ]
Brain, Etienne [2 ]
Mauriac, Louis [1 ]
机构
[1] SW Comprehens Canc Ctr, Dept Med Oncol, Inst Bergonie, F-33076 Bordeaux, France
[2] Ctr Rene Huguenin, F-92211 St Cloud, France
关键词
Capecitabine; Chemotherapy; Elderly; Metastatic breast cancer; Retrospective; Prognosis analysis; PHASE-II TRIAL; PEGYLATED LIPOSOMAL DOXORUBICIN; ELDERLY-PATIENTS; WEEKLY PACLITAXEL; VINORELBINE; CAPECITABINE; WOMEN; CYCLOPHOSPHAMIDE; COMBINATION; MULTICENTER;
D O I
10.1016/j.critrevonc.2010.10.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Data on chemotherapy for elderly patients with metastatic breast carcinoma (MBC) are limited. We performed a 7-year retrospective analysis of MBC patients at our institution receiving first-line chemotherapy aged >= 75 years. Of 117 patients, 103 received monotherapy (67 capecitabine, 29 vinorelbine, 5 docetaxel, 2 liposomal doxorubicin) and 14 received polychemotherapy (12 anthracycline-based, 2 vinorelbine-gemcitabine). Chemotherapy demonstrated acceptable tolerability. Median progression-free survival (PFS) and overall survival (OS) from initiation of chemotherapy were 6.2 months and 13.8 months, respectively. At 2 years, 25% of patients were alive; however, 25% died within 3 months of beginning chemotherapy. Independent prognostic factors for longer PFS were good performance status, absence of visceral disease and capecitabine treatment. Good performance status and lack of visceral disease were also significant for OS. These results suggest that palliative chemotherapy should not be systematically excluded in this setting, but should be carefully discussed as it appears to be feasible with apparent benefit in selected patients. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:171 / 179
页数:9
相关论文
共 50 条
  • [21] Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients
    Andrea Michelotti
    Marco Venturini
    Carmelo Tibaldi
    Carmelo Bengala
    Luigi Gallo
    Flavio Carnino
    Lucia Del Mastro
    Rita Lionetto
    Elda Montanaro
    Riccardo Rosso
    Pierfranco Conte
    Breast Cancer Research and Treatment, 2000, 59 : 133 - 139
  • [22] Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients
    Michelotti, A
    Venturini, M
    Tibaldi, C
    Bengala, C
    Gallo, L
    Carnino, F
    Del Mastro, L
    Lionetto, R
    Montanaro, E
    Rosso, R
    Conte, P
    BREAST CANCER RESEARCH AND TREATMENT, 2000, 59 (02) : 133 - 139
  • [23] Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
    Valerio, Maria Rosaria
    Spadaro, Pietro
    Arcana, Concetta
    Borsellino, Nicolo
    Cipolla, Calogero
    Vigneri, Paolo
    Piazza, Dario
    Gebbia, Vittorio
    FUTURE SCIENCE OA, 2021, 7 (10):
  • [24] First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
    Pilar García-Alfonso
    Eduardo Díaz-Rubio
    Albert Abad
    Alfredo Carrato
    Bartomeu Massutí
    María José Ortiz-Morales
    José Luis Manzano Mozo
    Andrés Muñoz
    Gema Durán
    Javier Sastre
    María José Safont
    Reyes Ferreiro
    Fernando Rivera
    Encarnación González
    Manuel Valladares-Ayerbes
    Cristina Grávalos
    Vicente Alonso-Orduña
    José María Viéitez
    Alfonso Yubero
    Enrique Aranda
    Drugs & Aging, 2021, 38 : 219 - 231
  • [25] First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
    Garcia-Alfonso, Pilar
    Diaz-Rubio, Eduardo
    Abad, Albert
    Carrato, Alfredo
    Massuti, Bartomeu
    Ortiz-Morales, Maria Jose
    Manzano Mozo, Jose Luis
    Munoz, Andres
    Duran, Gema
    Sastre, Javier
    Safont, Maria Jose
    Ferreiro, Reyes
    Rivera, Fernando
    Gonzalez, Encarnacion
    Valladares-Ayerbes, Manuel
    Gravalos, Cristina
    Alonso-Orduna, Vicente
    Vieitez, Jose Maria
    Yubero, Alfonso
    Aranda, Enrique
    DRUGS & AGING, 2021, 38 (03) : 219 - 231
  • [26] First-line chemotherapy with or without biologic agents for metastatic breast cancer
    Andreetta, Claudia
    Minisini, Alessandro M.
    Miscoria, Manuela
    Puglisi, Fabio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 76 (02) : 99 - 111
  • [27] Combination of docetaxel and doxorubicin as first-line chemotherapy in metastatic breast cancer
    Baltali, E
    Özisik, Y
    Güler, N
    Firat, D
    Altundag, K
    TUMORI, 2001, 87 (01) : 18 - 19
  • [28] WEEKLY EPIRUBICIN AND DOCETAXEL AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER
    D'Ottavio, A.
    Vaccaro, A.
    Belli, F.
    Nunziata, C.
    Meliffi, L.
    Moscetti, L.
    Barduagni, M.
    Sperduti, I.
    Gamucci, T.
    ANNALS OF ONCOLOGY, 2004, 15 : 19 - 19
  • [29] Outcomes of first-line chemotherapy for visceral crisis in metastatic breast cancer
    Andrade, Matheus de Oliveira
    Felix, Vitor Hugo
    Bonadio, Renata Colombo
    Testa, Laura
    CANCER RESEARCH, 2024, 84 (09)
  • [30] Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study
    Inal, Ali
    Kaplan, M. Ali
    Kucukoner, Mehmet
    Urakci, Zuhat
    Guven, Mehmet
    Nas, Necip
    Yunce, Muharrem
    Isikdogan, Abdurrahman
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (08) : 3869 - 3872